India began administration of COVID-19 vaccines on 16 January 2021. As of 4March2023[update], India has administered over 2.2 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines.[2][3] In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated.[4][5]
According to a June 2022 study published in The Lancet, COVID-19 vaccination in India prevented an additional 4.2 million deaths from December 8, 2020, to December 8, 2021.[8][9]
Vaccination programme
Cumulative doses administered across the country
Total doses administered across the country as of March 4, 2023 [10][5]
Dose
Vaccination (Percentage of eligible population vaccinated)
Partially Vaccinated
1,025,789,302(94.61)
Fully Vaccinated
952,033,158(87.81)
Precautionary(Booster) Dose
228,593,024
Monthly graph of cumulative doses administered across the country
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org.
Graph of daily doses administered across the country
Graph of daily doses administered. Last updated: March 4, 2023[11]
Citizens above the age of 12 can book appointments through the COWIN platform or can do a Walk-In registration on site. All vaccine centres have registration desks, vaccine booths and observation rooms. Vaccine certificates can be downloaded digitally through the COWIN platform, or citizens can ask for a hard copy from vaccination centres. All government run vaccination centers provide free of cost vaccines, private centers do charge.[13]
Background and timeline
A vaccination centre in Delhi.India's COVID-19 vaccination deployment until 3 June
First Phase, initial approvals, launch of vaccination programme
In September 2020, India's Health minister Harsh Vardhan stated that the country planned to approve and begin distribution of a vaccine by the first quarter of 2021.[14] The first recipients were to be 30 million health workers directly dealing with COVID patients.[15]
A vial of Covishield, the Indian-manufactured version of the AstraZeneca vaccine.
A vial of Covaxin
Vaccination drive for COVID prevention in Bhopal, India
On 1 January 2021, the Drug Controller General of India (DCGI) approved emergency use of the Oxford–AstraZeneca vaccine (local trade name "Covishield").[16][17][18] On 2 January, the DCGI also granted an interim emergency use authorisation to BBV152 (trade name "Covaxin"), a domestic vaccine developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology.[19] This approval was met with some concern, as the vaccine had not then completed phase 3 clinical trials.[20] Due to this status, those receiving Covaxin were required to sign a consent form,[21] while some states chose to relegate Covaxin to a "buffer stock" and primarily distribute Covishield.[22]
COVID-19 vaccination roll out in AIIMS, New Delhi, India on 16 January 2021
India began its vaccination programme on 16 January 2021, operating 3,006 vaccination centres on the onset.[23] Each vaccination centre will offer either Covishield or Covaxin, but not both.[24] 165,714 people were vaccinated on the first day of availability. Difficulties in uploading beneficiary lists at some sites caused delays.[25] In the first three days, 631,417 people were vaccinated. Of these, 0.18% reported side-effects and nine people (0.002%) were admitted to hospitals for observation and treatment.[26][27] Within those first days, there were concerns about low turnout, due to a combination of vaccine safety concerns, technical problems with the software used, and misinformation.[28]
The first phase of the rollout involved health workers and frontline workers, including police, paramilitary forces, sanitation workers, and disaster management volunteers.[23] By 1 March, only 14 million healthcare and frontline workers had been vaccinated, falling short of the original goal of 30 million.[29]
Second phase
The next phase of the vaccine rollout covered all residents over the age of 60, residents between the ages of 45 and 60 with one or more qualifying comorbidities, and any health care or frontline worker that did not receive a dose during phase 1. Online registration began on 1 March via the Aarogya Setu app and Co-WIN ("Winning over COVID-19") website.[30][31][32] Amid the beginnings of a major second wave of infections in the country,[33][34][35] vaccine exports were suspended in March 2021, and the government ordered 110 million Covishield doses from SII.[36] The company aims to produce 100 million doses per month, but by May 2021 its production capacity was only 60–70 million doses.[37][38] Following the conclusion of its trial, the DCGI issued a standard emergency use authorisation to Covaxin on 11 March 2021.[39]
From 1 April, eligibility was extended to all residents over the age of 45.[40] On 8 April, Prime Minister Narendra Modi called for a four-day Teeka Utsav ("Vaccine Festival") from 11 to 14 April, with a goal to increase the pace of the program by vaccinating as many eligible residents as possible. By the end of the Utsav, India had reached a total of over 111 million vaccine doses to-date.[41][42][43]
Third phase, Sputnik V approval
On 12 April, the DCGI approved Russia's Sputnik V vaccine for emergency use in India. A phase 3 trial was conducted in the country in September 2020, which showed 91.6% efficacy.[44] The local distributor Dr. Reddy's Laboratories stated that it planned to have the vaccine in India by late May 2021.[45]
On 19 April, it was announced that the next phase of the vaccination programme would begin on 1 May, extending eligibility to all residents over the age of 18. Under phase 3, individual stakeholders were also given more flexibility in how they conduct the vaccination programme. As part of this plan, only half of the vaccines procured by the Central Drugs Laboratory from manufacturers would be distributed by the central government. This supply would go to government-run clinics and be offered free-of-charge to residents 45 and over and priority workers and siphoned off to states based on factors such as the number of active cases and how quickly they are administering vaccines. The remainder would be offered to individual states and purchased on the open market (including private hospitals), which would be able to serve residents over the age of 18.[46][47][48]
Registration for the next phase began on 28 April; a single-day record of nearly 13.3 million people registered.[49] Due to supply issues, several states, including Delhi, Gujarat and Madhya Pradesh announced that they would delay their wider rollouts of vaccines to later in the month.[50]
The initial shipment of 150,000 Sputnik V doses arrived on 1 May, and began to be administered on 14 May.[51][52][53] An estimated 156 million doses is expected between August and December; initially, doses will be sourced from Russia, but domestic production is expected to begin by August 2021.[54][55][56]
On 13 May, the DCGI approved phase 2 and phase 3 trials of Covaxin on children 2–18.[57] On 14 May, health officials projected that based on the anticipated approval of additional vaccine options, it could receive at least 2.17 billion more vaccine doses from August to December 2021.[58][59] On 25 May, India exceeded 200 million vaccine doses administered in total.[60] On 3 June, the Ministry of Health and Family Welfare pre-ordered 300 million doses of a potential fourth vaccine, Corbevax, which is undergoing phase 3 clinical trials.[61]
On 23 May, the union government allowed walk-in registrations for vaccination throughout the country; a health worker at the vaccination centre would register the recipient in the Co-win vaccination database. The government claimed in an affidavit to the Supreme Court that as of June 23 about 78 per cent of vaccines had been administered via walk-in registration.[62]
Return to centralised procurement
On 31 May, an affidavit was issued in the Supreme Court of India requesting a review of the central government's vaccine distribution strategy, suggesting that the decision to only offer doses at no charge to priority workers and residents over the age of 45 was "prima facie arbitrary and irrational".[63]
On 7 June, Prime Minister Modi announced that India would migrate back to centralised procurement of vaccines by 21 June. In an address, Modi stated that multiple chief ministers had requested that the central government reconsider its new distribution strategy and reinstate the system it had used before May. As before, the centre will procure up to 75% of the country's vaccine supplies from manufacturers in bulk and distribute them to states at no additional charge. Vaccines would now be offered at no charge for those in the 18–44 age group. Private hospitals will still be responsible for the remaining 25% of procurement, but fees for appointments are now capped at ₹150 (US$1.80).[64][65]
On 21 June, the day these changes took effect, approximately 8,270,000 doses were administered—India's largest single-day total until that point. The states of Madhya Pradesh and Karnataka had the highest local totals.[66][67][68]Member of Parliament, Rajya SabhaP. Chidambaram accused Bharatiya Janata Party of having "hoarded" vaccine doses in the days leading up to 21 June in order to encourage larger numbers; seven states controlled by the BJP were among the top ten states to have administered vaccine doses that day, few of these states had below-average vaccination numbers in the days leading up to 21 June (such as Madhya Pradesh, which went from 692 doses on 20 June to 1,690,000 the next day, and numbers had dropped significantly in the state the next day).[69][70][71][72]
On 23 June, India surpassed over 300 million vaccine doses administered in total.[73] On 28 June, India overtook the United States in total vaccine doses administered.[74] On 29 June, the DCGI approved the Moderna vaccine (which is being imported by Cipla) for emergency use. Vinod Kumar Paul stated that the Pfizer vaccine was also likely to be approved soon.[75][76]
500 million mark, Johnson & Johnson Covid-19 vaccine approval and record
On 6 August 2021, India crossed the 500 million doses milestone within 6 months from the onset of the vaccination program.[77]
On 7 August 2021, the Drug Controller General of India (DCGI) approved emergency use of the Johnson and Johnson single-dose vaccine.[78] On 16 Aug 2021, India administered around 8.81 million doses of COVID-19 vaccines, achieving the highest single-day record and overtaking its own previous record of 8.61 million doses, by 16 August the cumulative doses had surpassed the 550 million mark.[79][80]
ZyCoV-D approval for ages 12 & above and single day vaccination records
On 20 August 2021, India granted emergency authorization to Zydus Cadila's vaccine ZyCoV-D, the world's first DNA plasmid-based COVID-19 vaccine, for patients 12 and older.
India granted emergency use approval to the world's first DNA based COVID-19 vaccine, manufactured by for adults and children aged 12 years and above. The vaccine is administered using a needle-free applicator.[81][82] The government announced on 30 September 2021 that the ZyCoV-D vaccine will be a three dose vaccine and it will be included in the Covid vaccination programme of India.[83]
Since August 10, 2021, foreign nationals residing in India can now receive the COVID-19 vaccine by registering themselves on the Cowin platform; like other eligible beneficiaries, the foreign nationals can book a slot via the portal and use their passport as a document to verify their identity for the registration process.[84]
By 26 August 2021, 50% of the adult population in India were inoculated with at least one dose of the approved vaccines, which included 99% coverage among healthcare workers and 100% front-line workers for the first dose.[85]
On 27 August 2021, India crossed the milestone of administering more than 10 million (1 crore) doses of COVID-19 vaccine in a single day, setting a new world record. Uttar Pradesh topped the list with 2.8 million doses, followed by Karnataka with 1 million doses and Maharashtra at third with 0.98 million doses.[86]
On 29 August 2021, Himachal Pradesh became the first state to complete administering first doses of COVID-19 vaccines to 100% of the population.[87] On 31 August, India again set another single-day vaccination record by inoculating around 12 million (1.2 Crore) doses in 24 hours.[88]
By September 2021, all adult people in Sikkim, Dadra and Nagar Haveli, Himachal Pradesh, Goa, Ladakh, and Lakshadweep have received at least one dose of Covid vaccine as the cumulative jabs administered in the country crossed 75 crores. Many city corporations, talukas, gram panchayats and districts had also administered the first dose of COVID-19 vaccination to 100 per cent of their adult population.[89][90][91]
As many as 25 million people were vaccinated on Narendra Modi's birthday on 17 September 2021. This is the highest single-day vaccination tally so far in the whole world.[92] There are allegations that a lot of pressure could have been put on officials to increase and twist to record vaccination numbers on the Prime Minister's birthday as some people who had not received their Covid shots somehow seem to have been issued vaccination certificates including those who are deceased.[93][94]
On 27 September, India administered over 1 crore vaccine doses for the fifth time, and total vaccination coverage crossed 86 crore (860 million).[95] On 2 October, this increased to 960 million.[96]
Booster doses and pediatric vaccines
By September 2021, several companies had received approval to begin clinical trials on COVID-19 vaccines for children.[97] Discussions were also emerging over whether India would utilize vaccine booster doses, with the government having maintained that they were studying their applicability, and that they were focused on their goal to administer a primary series of vaccine doses to all adults.[98] On 21 October 2021, India crossed the one billion mark for administered doses.[99]
On 26 December 2021, Prime Minister Modi announced that vaccine eligibility would be extended to youth 15 to 18 years of age from 3 January 2022 (with online registration opened on 1 January 2022); this age group would exclusively receive Covaxin. It was also announced that booster doses would become available from 10 January 2022, beginning with frontline workers, and residents over the age of 60 with comorbidities. Within this cohort, doses would be prioritized to those who had received their second dose at least nine months prior.[100][101]
On 14 March 2022, Union health minister Mansukh Mandaviya announced that vaccine eligibility would be extended to children 12–14, and that this group would exclusively receive Corbevax. Booster eligibility was also extended to all adults 60 and older.[102] On 8 April 2022, the Ministry of Health and Family Welfare announced that all adults 18 and over would become eligible for booster doses beginning 10 April, and that they would be available via private vaccination centres.[103]
In May 2022, the Supreme Court of India ruled that COVID-19 vaccine mandates were unconstitutional, citing the "emerging scientific opinion" that COVID-19 vaccines did not reduce the risk of transmission by those who are vaccinated.[104]
Vaccine development and distribution
Prime Minister Narendra Modi visiting the Serum Institute of India on 28 November 2020.
As of early May 2020, there were over 30 vaccine candidates in development in India, many of which were already in pre-clinical trials.[105]
The Pune-based Serum Institute of India (SII) is the world's largest vaccine maker. This existing capacity enabled India to be a major participant in the COVAX programme to distribute vaccines to developing countries.[106] In February 2020, SII had begun animal trials of vaccine candidates.[107] SII announced in April 2020 that it would apply for clinical trials from the Drug Controller General of India (DCGI) in April 2020. SII president Adar Poonawalla said that a vaccine would be delivered within a year, but projected an efficacy between 70 and 80%.[108]
In August 2020, SII received approvals for phase 2 and phase 3 trials of its version of a vaccine being developed by AstraZeneca and the University of Oxford's Vaccitech.[109] SII joined GAVI in a partnership with the Bill & Melinda Gates Foundation to produce 100 million doses of vaccine for developing countries.[110] The SII planned to manufacture 1.5 and 2.5 billion doses of the AstraZeneca vaccine per-year under the trade name "Covishield".[111] By its approval in January 2021, the company had stockpiled 50 million doses, but well short of its own target of 400 million.[112][113] The government ordered 21 million doses to be delivered by February, but the company said no indication of any further orders were given.[36] The company began to export the remaining stocks instead.[111]
Hyderabad-based Bharat Biotech, in collaboration with U.S.-based FluGen, expected to begin the first clinical trials of a nasal vaccine by late-2020.[114] The Indian Council of Medical Research partnered with Bharat Biotech in May 2020 to develop a COVID vaccine entirely within India.[115] In June 2020, it received DCGI approval to begin phase 1 and phase 2 trials on its vaccine, BBV152 (trade name "Covaxin").[116] In September 2020, it was reported that in pre-clinical trials on animals, Covaxin was able to build immunity.[117] In July 2021, Bharat Biotech reported the vaccine to be 64% (95% CI, 29–82%) effective against asymptomatic cases, 78% (65–86%) effective against symptomatic cases, 93% (57–100%) effective against severe COVID-19 infection, and 65% (33–83%) effective against the Delta variant.[118][119] On 20 April 2021, Bharat Biotech announced that it had expanded its production capabilities for Covaxin to 700 million doses per-year.[120]
Cadila Healthcare began vaccine development in March 2020, including a viral vector vaccine and a DNA plasmid vaccine.[121][122] In mid-July 2020, Cadila held early human trials of its vaccine candidate ZyCoV-D,[123] and received approval for phase 3 trials in January 2021.[124][125] It began large-scale production in April 2021, with Cadila expecting to receive emergency authorisation between May and June 2021.[126] On 1 July 2021, Cadila Healthcare reported the efficacy to be 66.6% against symptomatic COVID-19 and 100% against moderate or severe disease in its interim analysis of its phase 3 trial data.[127][128]
In September 2020, Dr. Reddy's partnered with the Russian Direct Investment Fund (RDIF) to conduct phase 3 trials of the Sputnik V vaccine in India, and to distribute the vaccine there once approved.[129][130] In April 2021, RDIF CEO Kirill Dmitriev told NDTV that they had "five great manufacturers in India" who would be producing the vaccine, and felt that the country could become Sputnik V's "production hub" for use and export.[131] Dr. Reddy's is also working with the RDIF on approval of "Sputnik Light"—a regiment of Sputnik V consisting only of the first dose.[56]
In April 2021, phase 3 clinical trials were approved for another vaccine, Corbevax, a protein subunit that is being developed by BioE, the Baylor College of Medicine, and Dynavax Technologies.[61][132]
In mid-July, it was reported that approval of the Moderna and Pfizer vaccines, as well as a shipment of vaccines donated by the United States (which includes the AstraZeneca, Janssen, Moderna, and Pfizer vaccines), had faced delays due to requests from their manufacturers for indemnity clauses from Indian authorities, which would relieve them from legal liability for adverse reactions.[134][135]
On 21 September 2021, the Indian Government said that it will not purchase the Pfizer-BioNTech and Moderna vaccines as domestic output of more affordable and easier-to-store vaccines has jumped.[136]
In the Quad summit, Prime Minister Narendra Modi announced that India would make 8 million doses of J&J vaccine available by the end of October under the Quad vaccine partnership. It will be manufactured in India by the Biological E. This would be ready by the end of October, compatible with our decision to resume vaccine export.[137]
On 6 February 2022, DCGI approved Sputnik Light Covid vaccine for emergency use in India.[138]
Vaccine deployment strategies
Optimizing vaccination deployment for India[139] includes tailoring of strategies to the demographic and epidemiologic situation by modeling vaccination scenarios,[140] explore measures to reach children at risk[141] and co-optimizing vaccination strategy for societal and individual benefit in parallel.[142]
In September 2021, India's government announced that it would not buy COVID-19 shots from Pfizer (PFE.N)/BioNTech (22UAy.DE) and Moderna (MRNA.O), mainly because the domestic output of more affordable and easier-to-store vaccines of Serum Institute of India, Bharat Biotech & Cadila Healthcare has jumped. India will make 8 million doses of the Johnson and Johnson vaccine available by the end of October under the Quad vaccine partnership.[137][155]
Vaccine Maitri (English:Vaccine Friendship)[166] is a humanitarian initiative undertaken by the Indian government to provide COVID-19 vaccines to countries around the world.[167] The government started providing vaccines from 20 January 2021. As of 6March 2022, India had delivered around 16.3 cror doses of vaccines to 96 countries.[168] Of these, 1.43 cror doses were gifted to 46 countries by the Government of India. The remaining 10.71 cror were supplied by the vaccine producer under its commercial and, 4.15 cror doses were supplied throw COVAX obligations. In late March 2021, the Government of India temporarily froze exports of the Covishield, citing India's own COVID crisis and the domestic need for these vaccines.[169] The Health Minister of India, Mr. Mansukh Mandaviya announced in September that India will resume the export of vaccines from October to the rest of the world.[170][171]
Countries that received doses of the Indian-made Covaxin as of 6March 2021
200,000 doses of COVID-19 vaccines were gifted by India to the UN peacekeepers on 27 March to be distributed to all peacekeeping missions.[172]
Vaccines
India has two approved COVID-19 vaccines: Covishield and Covaxin. Both of them were exported and used in foreign grants by the Government of India.
India kicked off international shipment of the vaccines on 20 January 2021, only four days after starting its own vaccination program.[176] Bhutan and Maldives were the first countries to receive vaccines as a grant by India. This was quickly followed by shipments to Nepal, Bangladesh, Myanmar and Seychelles.[176] By mid-March 2021, India was also supplying vaccines on a commercial basis to countries including Canada,[177] the UK,[178] and Saudi Arabia.[179]
As of 21 February 2022, India had exported total 16,29,63,500 doses including 1,42,67,000 vaccine provided as grant to more than 96 nations and, UN Peacekeepers and UN Health workers.[168]
The Serum Institute of India was selected as a key supplier of cost-effective COVID-19 vaccines to the COVAX initiative,[180] 19.8 million doses of Covishield vaccines were supplied by India to various countries through the initiative.[168] In May, when COVAX was already short 140 million doses,[181] the Serum Institute announced that it expected to maintain its suspension of vaccine deliveries to COVAX through the end of 2021[182] due to the second wave of COVID-19 in India[183] and the US ban on export of key raw materials.[184]
International reaction
International organizations
IMF: IMF chief economist Gita Gopinath lauded India for playing a key role during the crisis by dispatching vaccines to many countries. She said "I also want to mention that India really stands out in terms of its vaccine policy. If you look at where exactly is one manufacturing hub for vaccines in the world–that will be India."[185]
Countries
Jamaica[186] of the OACPS has thanked Indian efforts in delivering vaccines to developing and least developed countries.
Nepal Prime minister Khadga Prasad Oli thanked India stating; "We got an early chance to administer the Covid-19 vaccine. For this, I thank our neighbouring nation India, its government, the people, and especially Prime Minister Narendra Modi. They sent 10 lakh doses of vaccines to us as a grant within a week of the roll-out in India."[187]
Barbados Prime Minister Mia Amor Mottley thanked Prime Minister Narendra Modi for the supply of "Made in India" COVID-19 vaccines. She tweeted, "PM Modi made it possible for more than 40,000 persons in Barbados and tens of thousands elsewhere, to receive their 1st dose of COVISHIELD via Vaccine Maitri before receiving his. A genuine demonstration of generosity. Thank you and we wish you continued good health."[189]
Antigua and Barbuda Prime Minister Gaston Browne had thanked Prime Minister of India Narendra Modi "for demonstrating an act of benevolence, kindness and empathy", for sending vaccines to Caribbean countries.[190]
Afghanistan Afghanistan's ambassador to India Farid Mamundzay said "Thank you, India for providing Afghan people lifesaving gift on the first day of 2022!"[191]
As of March 4, 2023, populations above the age of 12 are only eligible for vaccination. The percentage of population inoculated shown in the table above is according to the 2021 projected population of India with all age groups. According to the government, based on the projected mid-year count for 2021, the country's total population aged 12 years and above is approximately 108 crore. Around 94.61% of the 12+ population of the country have received at least one dose of the COVID-19 vaccine since the vaccination drive began. In addition to this, 87.81% of the eligible population has been fully vaccinated.[195]
Vaccine acceptance in India
Over 80% of the population of India have a positive response for getting anti covid shots. India has one of the lowest vaccine hesitancy in the world.[196] There was vaccine hesitancy in the initial months of 2021, especially in rural India and among poor and tribal populations. Constant government and public awareness drastically reduced vaccine hesitancy. Since May 2021, more than half of daily doses administered in India have been from rural parts.[197] Vaccine centers in India have witnessed large number of people willing to get covid vaccine resulting in overcrowding and mismanagement. Many centers across India in months of April & May reported severe shortage of covid vaccines due to large crowds turning up for vaccination. In cities like Mumbai, New Delhi, Bengaluru many people even after waiting for hours did not receive their covid vaccine due to shortage.[198] Since July, vaccine supply has drastically increased thus India is vaccinating at a very fast pace.[199]
One study published on vaccine acceptance shows that 79.5% of people from Delhi want to take a COVID-19 vaccine.[200] In another study which was published from West Bengal, a state in Eastern India, has shown that 77.27% of people want to take the COVID-19 vaccine.[201] According to the finding from these two studies, it can be expected that over 75% of people want to get a COVID-19 vaccine.
Uttar Pradesh achieved 100% first dose saturation in COVID-19 vaccination, with over 26 crore doses administered, highest in India. The entire eligible population received the first dose by Monday evening. Nearly 70% of the adult population was fully vaccinated. Health teams praised for administering over 7 crore doses in January.[202]
Adverse events
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org.
Like many other vaccinations, COVID-19 vaccines also have a risk of causing side effects. According to India's Union Ministry of Health and Family Welfare, the most common side-effects include pain or swelling at the injection site, fever, irritability and headaches.[203] The UK Government also lists fatigue, nausea and joint pain as common side-effects of the Oxford vaccine (known as Covishield in India).[204] Medical experts maintain that vaccines used are safe and their benefits outweigh the risks. It is also important to note that adverse cases do not necessarily have a causal relationship with the vaccines.[205]
A total of 617 serious adverse events were reported until March 29. Of these, 180 cases resulted in death. The Immunisation Technical Support Unit at the federal health ministry examined 192,000 case reports, including 12,400 deaths. In more than half of the examined cases of death, the cause of death was found to be acute coronary syndrome. However, the documentation had been completed for only 3,500 cases.[206]
By 7 June, 26,000 adverse events had been reported following immunisation. Of this, 24,901 were minor, 412 were significant and 887 were serious. 488 deaths were also reported, including 301 men and 178 women (details of 9 deaths were not available). Both vaccines had an adverse reaction rate of about 0.01% and a fatality rate of around 0.0001% - 24,703 events and 457 deaths from 210 million Covishield doses, 1,497 events and 20 deaths following 25 million Covaxin doses. Maharashtra reported the most adverse events (4,521), followed by Kerala (4,074), Karnataka (2,650) and West Bengal (1,456).[205][207]
On 15 June, the government published a review of case reports that had occurred between 5 February and 31 March 2021, focusing on 31 cases and one death from anaphylaxis that were believed to have been attributed to the vaccine, out of nearly 60 million doses administered in the time period. Only three of these cases, and the single death of a 68-year-old patient, were determined to be "vaccine-product related", with the remainder having been classified as coincidental, indeterminate, or unclassifiable. The report stated that "mere reporting of deaths and hospitalisations as serious adverse events does not automatically imply that the events were caused due to vaccines. Only properly conducted investigations and causality assessments can help in understanding if any causal relationship exists between the event and the vaccine."[208][209][210]
Related Research Articles
Serum Institute of India (SII) is an Indian biotechnology and biopharmaceuticals company, based in Pune. It was founded by Cyrus Poonawalla in 1966 and is a part of Cyrus Poonawalla Group.
The first case of the COVID-19 pandemic in India was reported on 30 January 2020, originating from China. Slowly, the pandemic spread to various states and union territories including the Indian-administered union territory of Jammu and Kashmir. Two suspected cases with high virus load were detected and isolated on 4 March in Government Medical College, Jammu. One of them became the first confirmed positive case on 9 March 2020. Both individuals had a travel history to Iran.
The first case of the COVID-19 pandemic in India was reported on 30 January 2020, originating from China. Slowly, the pandemic spread to various states and union territories including the state of Telangana. The first case was recorded in this region on 2 March from a man who had travel history with the UAE.
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company based in Hyderabad, which is engaged in drug discovery, drug development, and the manufacture of vaccines, biotherapeutics, pharmaceuticals and healthcare products.
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.
Sputnik V or Gam-COVID-Vac is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.
Covaxin is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.
The COVID-19 vaccination program in the Philippines was a mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a day after the arrival of the country's first vaccine doses which were donated by the Chinese government.
The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.
ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.
On 29 January 2021, Algeria launched a COVID-19 vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.
Vaccine Maitri is a humanitarian initiative undertaken by the Indian government to provide COVID-19 vaccines to countries around the world. The government started providing vaccines from 20 January 2021. As of 21February 2022, India had delivered around 16.29 crore doses of vaccines to 96 countries. Of these, 1.43 crore doses were gifted to 98 countries by the Government of India. The remaining 10.71 crore were supplied by the vaccine producers under its commercial and 4.15 crore were supplied by COVAX obligations. In late March 2021, the Government of India temporarily froze exports of the Covishield, citing India's own COVID crisis and the domestic need for these vaccines. The Health Minister of India, Mansukh Mandaviya announced in September that India will resume the export of vaccines from October to the rest of the world.
COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. As of October 2023, 51.8% of the continent's population is fully vaccinated with over 1084.5 million doses administered.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.
The COVID-19 vaccination campaign in Brazil is an ongoing mass immunization campaign for the COVID-19 pandemic in Brazil. It started on January 17, 2021, when the country had 210 thousand deaths.
Nepal began administration of COVID-19 vaccines on 27 January 2021. 1 million Oxford-Astrazeneca vaccines were provided by India as a grant while Nepal brought 2 million doses from Serum Institute of India (SII) and was one of the first to receive COVID-19 vaccines. The delivery of the first 1 million doses arrived on 21 February. In March, India's decision to ban exports of vaccines created uncertainty over whether Nepal would be able to continue its vaccinations. By April, SII had only provided half of the 2 million doses for which Nepal had paid in full. A spokesperson for the Indian Ministry of External Affairs rejected the notion of an export ban and said "We will export vaccines taking into account the domestic demand." By late July, there was still uncertainty in Nepal over when SII would deliver the vaccines that were purchased, although Prime Minister Narendra Modi said India would "resume the supply of vaccines soon."
COVID-19 vaccination in Eswatini is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
CoWIN is an Indian government web portal for COVID-19 vaccination registration, owned and operated by India's Ministry of Health and Family Welfare. It displays booking slots of COVID-19 vaccine available in the nearby areas and can be booked on the website. The site also provides vaccination certificates to the beneficiaries, which act as Vaccine Passports during the COVID-19 pandemic for the beneficiaries and can be stored in Digilocker. Users can access the platform via desktop, tablet, and mobile phones.
References
Footnote references
↑ All government run vaccination centers provide free of cost vaccines
↑ Vaccination Centres/facilities charge as per dose
↑ "Vaccination state wise". Ministry of Health and Family Welfare. Archived from the original on 30 January 2020. Retrieved 4 March 2023. (NB: The data on this site change daily)
↑ Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, etal. (2 July 2021). "Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial". medRxiv10.1101/2021.06.30.21259439v1.
↑ Islam, F., Agarwalla, R., Panda, M., Alvi, Y., Singh, V., Debroy, A., Ray, A., Vadnerkar, A. and Uttekar, S., 2021. Assessment of the knowledge, preferences and concern regarding the prospective COVID-19 vaccine among adults residing in New Delhi, India-A cross-sectional study. medRxiv.
↑ Gautam, A., Dhara, B., Mukherjee, D., Mukhopadhyay, D., Roy, S., Ganguly, S.S., Chowdhury, A.D., Goswami, S., Dey, S., Basu, S. and Chatterjee, S., 2020. A Digital Survey on the Acceptance and Affordability of COVID 19 Vaccine among the People of West Bengal, India-A Survey Based Study. medRxiv.
↑ "Information for UK recipients"(PDF). Medicines and Healthcare Products Regulatory Agency, UK. Archived(PDF) from the original on 16 June 2021. Retrieved 21 June 2021.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
India 
COVID-19 portal 
